A recent survey commissioned by our company across more than 50 small, mid-sized, and large biopharmaceutical companies worldwide, shed light on the key reasons why biotechs outsource their early biologic development and manufacturing to a CDMO. In this 20-min panel discussion, members of our End-to-End Solutions team, part of the BioReliance® portfolio, will offer their perspectives on what we heard from respondents.
We discuss major hurdles biotechs mentioned and how a customer-centric CDMO partnership can help overcome these, dismissing the idea of one-size-fits-all.
In this webinar, you will learn about:
<ul>
<li>Top reasons to outsource to a CDMO</li>
<li>Overcoming hurdles with a CDMO partnership</li>
<li>What early-stage biotechs should look for in a CDMO</li>
</ul>

aem-GridColumn aem-GridColumn--default--9

<h2 class="webinar-subtitle">WEBINAR</h2>

Outsourcing Early Biologic Development to CDMOs

aem-GridColumn aem-GridColumn--default--9 aem-GridColumn--offset--default--0 aem-GridColumn--default--none

aem-GridColumn aem-GridColumn--default--3 aem-GridColumn--offset--default--0 aem-GridColumn--default--none

Webinar highlights global survey on key reasons for outsourcing early-stage pipeline to a CDMO by biopharmaceutical companies.